Press Releases

Twitter iconYouTube iconFacebook iconSoundCloudiTunes badge

Call us: +44 (0)20 7679 9041


The UCL Media Relations team is the university’s central press office.


We connect journalists to expert academics and promote UCL research and teaching throughout the global media.


More contact information



First baby tested for BRCA1 before conception born in UK

Publication date: Jan 9, 2009 10:26:05 AM

The first baby tested preconceptionally for a genetic form of breast cancer (BRCA1) has been born. The mother and her little girl are doing very well.

The birth is the first of its type to take place in the UK. Women who carry this form of genetic variation have an 80 per cent chance of developing breast cancer and a 60 per cent chance of developing ovarian cancer during their lifetime. In addition, BRCA1 carriers have a 50 per cent chance of passing on this anomaly to each of their children.

Mr Paul Serhal, Honorary UCLH Consultant/UCL Lecturer and Medical Director of the Assisted Conception Unit, commented: “This little girl will not face the spectre of developing this genetic form of breast cancer or ovarian cancer in her adult life. The parents will have been spared the risk of inflicting this disease on their daughter. The lasting legacy is the eradication of the transmission of this form of cancer that has blighted these families for generations.”

Patients who are offered this form of diagnosis have devastating family histories of serious illness and early deaths due to breast and ovarian cancers.

Preimplantation Genetic Diagnosis (PGD) involves undertaking an In Vitro Fertilisation (IVF) treatment cycle in order to have a number of embryos available for specific genetic testing. PGD provides information regarding the genetic status of the embryo, to be known prior to conception. It has the added advantage of avoiding the potential dilemma and physical and emotional trauma of undergoing a termination of an affected pregnancy.

Scientists and doctors at the Assisted Conception Unit and the PGD group at the UCL Institute for Women’s Health have pioneered and successfully applied this technology for avoiding transmission of cancer predispositions in a whole host of cancers. This includes a genetic form of bowel cancer (APC) and a genetic form of cancer of the retina (retinoblastoma).

Professor Ian Jacobs, Director of the UCL Institute for Women’s Health, added: “This is a wonderful example of what can be achieved for individual people and families by outstanding scientists, researchers and clinicians in the university and NHS working closely together as a collaborative team.”

-ENDS-

Notes for Editors

1.) PLEASE NOTE: The family concerned wish to remain anonymous and do not want to be contacted, therefore no further personal details can be given to the media about this case.

2.) The PGD team at UCL is led by Dr Sioban SenGupta and Karen Fordham.

3.) The Assisted Conception Unit is a private clinic, based at University College Hospitals NHS Foundation Trust (UCLH).

4.) For more information, please contact Ruth Metcalfe in the UCL Media Relations Office on tel: +44 (0)20 7679 9739, mobile: +44 (0)7990 675 947, out of hours: +44 (0)7917 271 364, e-mail: r.metcalfe@ucl.ac.uk

5.) UCL Institute for Women's Health: The Institute is a joint venture between UCL and UCLH to bring together leading academics and clinicians in women's health so that they can advance the healthcare of women in the UK and globally (www.instituteforwomenshealth.ucl.ac.uk)